Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:ATCCode |
C03XA01
|
| gptkbp:contraindication |
patients with liver impairment
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
tolvaptan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Jynarque
|
| gptkbp:indication |
gptkb:autosomal_dominant_polycystic_kidney_disease
|
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:mechanismOfAction |
vasopressin V2 receptor antagonist
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
thirst
liver injury polyuria |
| gptkbp:bfsParent |
gptkb:Otsuka_America_Pharmaceutical,_Inc.
|
| gptkbp:bfsLayer |
7
|